David Hung is back, launching a new oncology startup with $275M and big ambitions to make news in cancer drug development
After a brief and embarrassing side trip into Alzheimer’s research, biotech high flyer David Hung is back, and he’s jumping into oncology R&D once again with a brand new upstart and a whopping $275 million in backing.
Teaming back up with some of his former crew members at Medivation, which broke new ground in cancer drug development before the sale of the company to Pfizer for $14.3 billion, Hung says the stealth operation has a pipeline with 7 programs, each of which has multiple drug candidates.
Here’s the team at Nuvation Bio:
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 64,900+ biopharma pros reading Endpoints daily — and it's free.